Novo Kidney Trial Finds Ozempic Cuts Risk Of Major Cardiac Events and Death By 24%

A recent study conducted by Novo Nordisk, a leading pharmaceutical company, has unveiled promising results regarding the efficacy of their diabetes drug, Ozempic, in delaying the progression of chronic kidney disease (CKD) among diabetes patients. This large-scale late-stage trial has demonstrated a significant reduction in the risk of major cardiac events and death by 24% among participants.

Chronic kidney disease affects approximately 40% of individuals with type 2 diabetes globally, making it a significant health concern. Novo Nordisk’s decision to halt the trial ahead of schedule, almost a year earlier than planned, was driven by the interim analysis indicating the treatment’s success in achieving its primary endpoint.

According to Novo Nordisk, the trial, named FLOW, involved approximately 3,500 patients with type 2 diabetes and moderate to severe chronic kidney disease. Participants were administered 1 milligram (mg) of once-weekly semaglutide, in addition to standard care. The positive outcomes of the trial highlight the potential for semaglutide to emerge as a viable treatment option for individuals living with type 2 diabetes and chronic kidney disease.

These findings also underscore the broader medical benefits associated with drugs from the GLP-1 class, extending beyond their initial purposes of managing type 2 diabetes and promoting weight loss. However, despite the positive results, Novo Nordisk’s shares experienced a slight decline following the announcement, as the 24% reduction in the risk of kidney disease-related events fell slightly below some investors’ expectations.

The potential expansion of Ozempic’s label to include kidney disease treatment represents a significant step forward in addressing the unmet medical needs of diabetes patients with CKD. Novo Nordisk plans to submit applications for this label expansion to regulatory authorities in the European Union and the United States later this year.

The success of Ozempic in mitigating the risks associated with chronic kidney disease not only provides hope for improved outcomes among diabetes patients but also signals a potential breakthrough in the broader landscape of diabetes management and treatment.

Related posts:

Bempedoic Acid Cuts Cardiovascular Events In Statin-Intolerant Patients Novo Nordisk’s Controlling Shareholder Plans To Invest About $7 Billion a Year By 2030 Ozempic, Wegovy Face Stiff Challenge From Mounjaro, Orforglipron, and CagriSema for Weight Loss Novo Nordisk to Invest $2.3 Billion in France for Production Expansion